In this article, we will list the 5 Best CBD Stocks to Buy Right Now. Please visit 8 Best CBD Stocks to Buy Right Now if you would like to see the extended list and the methodology behind it.
5. Tilray Brands Inc (NASDAQ:TLRY)
Stock Upside Potential: 50.74%
Number of Hedge Fund Holders: 10
Tilray Brands Inc (NASDAQ:TLRY) is one of the best CBD stocks to buy right now. Although Tilray Brands Inc (NASDAQ:TLRY) stock is up only a modest 19% over the past year, analysts see the stock soaring more than 50% over the next 12 months.
On May 26, Tilray Medical joined talks on medical cannabis regulations in London. Tilray Medical is a subsidiary of Tilray Brands that offers a wide range of medical-grade CBD-products. The London talks brought together healthcare professionals, researchers, industry leaders, and policymakers to explore the future of medical cannabis innovation and regulation in Europe.
The forum included a panel discussion focused on clinical research, patient outcomes, and public health data to help shape evidence-based regulatory approaches.
According to José Tempero, Tilray Medical’s director of international medical affairs, the European medical cannabis field continues to evolve. In light of this, research and clinical evidence are critical to developing responsible frameworks and improving patient access.
Tilray Medical is a leading supplier of medical cannabis across five continents. According to Tilray Brands, the medical subsidiary has deep regulatory expertise and is well-positioned to continue advancing patient care across international markets.
Tilray Brands Inc (NASDAQ:TLRY) is a consumer packaged goods company. Its portfolio includes craft beer, spirits, medical and adult-use cannabis, and hemp wellness products. It operates dozens of brands and has footprints in more than 20 countries across the Americas and Europe.
4. Village Farms International Inc (NASDAQ:VFF)
Stock Upside Potential: 77.88%
Number of Hedge Fund Holders: 13
Village Farms International Inc (NASDAQ:VFF) is one of the best CBD stocks to buy right now. Village Farms stock has gained more than 110% over the past year, and analysts expect it to rise more than 77% over the next 12 months.
Village Farms International Inc (NASDAQ:VFF) reported its Q1 2026 results on May 11, revealing a 27% YoY jump in net sales to $50.2 million. This topline growth was driven by international export sales that soared 171% YoY to a record $14.6 million. The Netherlands was one of the company’s fastest-growing international markets, with sales there surging 448%. In Germany, the company continued to grow its market share and benefit from stable pricing.
Village Farms delivered net income of $4.8 million, reflecting a 68% YoY increase. It exited the quarter with $50.5 million in cash.
Village Farms’ Pure Sunfarms brand, through which it sells various CBD products, continued to expand its share of the dried flower format in Canada. Village Farms has recently expanded its cannabis production capacity and expects the expansion projects to fuel sales growth in the remainder of 2026 and into 2027.
Village Farms International Inc (NASDAQ:VFF) is a global cannabis company based in Canada. It produces and distributes a wide variety of cannabis and hemp-derived products for wellness and recreational use. Village Farms also has agricultural and clean energy interests.
3. Organigram Global Inc (NASDAQ:OGI)
Stock Upside Potential: 142.91%
Number of Hedge Fund Holders: 4
Organigram Global Inc (NASDAQ:OGI) is one of the best CBD stocks to buy right now. Analysts expect Organigram Global shares to explode by more than 140% over the next 12 months.
On May 12, Organigram Global Inc (NASDAQ:OGI) reported its March quarter results and issued guidance for 2026 revenue. The March quarter report showed net revenue declined 9% YoY to $59.8 million. Adjusted EBITDA of $0.9 million compared with $4.9 million a year ago.
The company said that weakness in its vapes business, infused pre-roll production challenges, and slower industry growth led to the quarterly declines. The company booked lower vape and pre-roll sales in the latest quarter than it did a year ago.
Organigram CEO James Yamanaka said they acted quickly to address these issues. As a result, product enhancements and operational adjustments that the company implemented are stabilizing performance. The company also expects the improvement in yields and flower potency as well as the contribution from Sanity Group to drive performance improvement in the second half of 2026.
Sanity is a Germany-based cannabis company that Organigram acquired at the end of the March quarter. Sanity has a diversified cannabis business and expanding operations across Europe, including footprints in the UK, Poland, Switzerland, and Czechia. Organigram expects Sanity to generate roughly €25 million in quarterly revenue over the next year. In light of the expected Sanity contribution, Organigram raised its 2026 revenue outlook to $350 million from the previous $300 million.
Organigram Global Inc (NASDAQ:OGI) is a Canadian company that grows cannabis and manufactures a variety of cannabis-derived products for recreational and wellness use. Its product range includes CBD-infused edibles under the Monjour brand.
2. cbdMD Inc (NYSEAMERICAN:YCBD)
Stock Upside Potential: 162.85%
Number of Hedge Fund Holders: N/A
cbdMD Inc (NYSEAMERICAN:YCBD) is one of the best CBD stocks to buy right now. The stock has gained around 35% over the past six months, and analysts see more upside potential, expecting the stock to surge more than 160% over the next 12 months.
cbdMD Inc (NYSEAMERICAN:YCBD) reported its March quarter results on May 14. The report showed revenue increased 19% YoY and 12% sequentially to $5.6 million. The company said the topline growth reflected continued momentum in its core business as well as contributions from the newly acquired Bluebird Botanicals.
Bluebird is a long-standing and respected brand in the CBD industry. According to Ronan Kennedy, the CEO of CbdMD, the Bluebird acquisition is a case study for what they can do and sets the template for additional strategic acquisitions.
Looking ahead, the CbdMD management expects Bluebird to contribute more to both its topline and earnings as operational efficiencies are realized and additional products are rolled out. With the integration of Bluebird, CbdMD expects to realize operational efficiencies through consolidated manufacturing, supply chain, and shared services. In addition, the management expects the expanded product offering and cross-brand distribution to accelerate revenue growth.
Beyond the expected Bluebird contribution, the CbdMD management is also excited about the opportunities in the CMS BEI Medicare pathway activation. This program allows participants in certain centers to consult about incorporating hemp products to improve symptom control.
cbdMD Inc (NYSEAMERICAN:YCBD) produces and distributes hemp-derived CBD products for wellness. Its portfolio includes CBD oils, gummies, and sleep aids. While the company primarily offers CBD products for human consumption, it also provides pet-specific products.
1. SNDL Inc (NASDAQ:SNDL)
Stock Upside Potential: 193.10%
Number of Hedge Fund Holders: 13
SNDL Inc (NASDAQ:SNDL) is one of the best CBD stocks to buy right now. SNDL Inc (NASDAQ:SNDL) reported its Q1 2026 results on April 29, revealing a 4.4% YoY drop in revenue to $195.9 million. The company said it faced market headwinds in both its liquor and cannabis segments during the quarter.
SNDL’s combined cannabis segment revenue declined 3.8% to $91.8 million, and operating loss widened 20% to $5.8 million. The cannabis segment houses the company’s portfolio of CBD-infused products, such as the Pearls by Gron gummies.
Looking ahead, SNDL CEO Zach George said they anticipate improvements in the cannabis market in the back half of 2026. Citing the company’s solid financial position, the CEO stated that SNDL is well-positioned to take advantage of both organic and inorganic opportunities to enhance its portfolio and accelerate growth. SNDL closed Q1 with $213.4 million in cash and no debt.
The management mentioned disciplined capital allocation as a major priority. The team is also pursuing efficiency initiatives and profit-enhancement measures as it adjusts to the reality of the current market conditions. As part of the profit-enhancement efforts, SNDL is launching initiatives expected to add $20 million in operating income over the remainder of 2026.
Canada-based SNDL Inc (NASDAQ:SNDL) is engaged in the liquor and cannabis retail businesses. The company’s cannabis division produces and distributes a suite of products, including CBD-based topicals, beverages, and edibles like gummies and chocolates.
While we acknowledge the potential of SNDL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SNDL and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 10 Most Buzzing AI Semiconductor Stocks to Buy in 2026 and 11 Best Medical Technology Stocks to Buy Right Now.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.
